Robbie Marcus
Stock Analyst at JP Morgan
(3.87)
# 664
Out of 4,980 analysts
165
Total ratings
54.95%
Success rate
8.22%
Average return
Main Sectors:
Stocks Rated by Robbie Marcus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HTFL HeartFlow | Initiates: Overweight | $36 | $34.70 | +3.75% | 1 | Sep 2, 2025 | |
| COO The Cooper Companies | Maintains: Neutral | $76 → $66 | $68.25 | -3.30% | 6 | Aug 28, 2025 | |
| INSP Inspire Medical Systems | Downgrades: Neutral | $195 → $110 | $81.47 | +35.02% | 6 | Aug 5, 2025 | |
| EW Edwards Lifesciences | Maintains: Neutral | $80 → $85 | $79.80 | +6.52% | 5 | Jul 25, 2025 | |
| NPCE NeuroPace | Maintains: Overweight | $14 → $16 | $9.97 | +60.48% | 5 | May 14, 2025 | |
| CVRX CVRx, Inc. | Downgrades: Underweight | $15 → $7 | $8.19 | -14.48% | 6 | May 9, 2025 | |
| ZBH Zimmer Biomet Holdings | Maintains: Overweight | $128 → $105 | $103.85 | +1.11% | 6 | May 6, 2025 | |
| IART Integra LifeSciences Holdings | Maintains: Underweight | $24 → $12 | $15.43 | -22.23% | 6 | May 6, 2025 | |
| CNMD CONMED | Maintains: Neutral | $70 → $58 | $53.98 | +7.45% | 7 | May 1, 2025 | |
| RXST RxSight | Downgrades: Underweight | $40 → $17 | $9.78 | +73.82% | 5 | Apr 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $120 | $91.65 | +30.93% | 1 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $38 → $36 | $24.45 | +47.24% | 17 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $420 → $445 | $392.76 | +13.30% | 9 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $575 → $675 | $467.54 | +44.37% | 5 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $12 → $13 | $7.27 | +78.82% | 3 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $110 | $108.09 | +1.77% | 13 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $280 → $330 | $352.82 | -6.47% | 4 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $32 | $11.86 | +169.81% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $40 | $36.04 | +10.99% | 5 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $75 → $85 | $78.40 | +8.42% | 2 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $90 | $78.71 | +14.34% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $53 → $50 | $31.19 | +60.31% | 2 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $8 | $7.37 | +8.62% | 2 | May 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $284 → $250 | $287.09 | -12.92% | 9 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $16 | $18.86 | -15.16% | 3 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $8 → $7 | $8.53 | -17.94% | 13 | Nov 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $17 | $15.30 | +11.11% | 2 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $125 → $118 | $131.95 | -10.57% | 5 | Oct 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $116 → $156 | $186.39 | -16.30% | 2 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $130 → $105 | $94.07 | +11.62% | 11 | Dec 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $55 → $40 | $90.91 | -56.00% | 2 | May 5, 2020 |
HeartFlow
Sep 2, 2025
Initiates: Overweight
Price Target: $36
Current: $34.70
Upside: +3.75%
The Cooper Companies
Aug 28, 2025
Maintains: Neutral
Price Target: $76 → $66
Current: $68.25
Upside: -3.30%
Inspire Medical Systems
Aug 5, 2025
Downgrades: Neutral
Price Target: $195 → $110
Current: $81.47
Upside: +35.02%
Edwards Lifesciences
Jul 25, 2025
Maintains: Neutral
Price Target: $80 → $85
Current: $79.80
Upside: +6.52%
NeuroPace
May 14, 2025
Maintains: Overweight
Price Target: $14 → $16
Current: $9.97
Upside: +60.48%
CVRx, Inc.
May 9, 2025
Downgrades: Underweight
Price Target: $15 → $7
Current: $8.19
Upside: -14.48%
Zimmer Biomet Holdings
May 6, 2025
Maintains: Overweight
Price Target: $128 → $105
Current: $103.85
Upside: +1.11%
Integra LifeSciences Holdings
May 6, 2025
Maintains: Underweight
Price Target: $24 → $12
Current: $15.43
Upside: -22.23%
CONMED
May 1, 2025
Maintains: Neutral
Price Target: $70 → $58
Current: $53.98
Upside: +7.45%
RxSight
Apr 4, 2025
Downgrades: Underweight
Price Target: $40 → $17
Current: $9.78
Upside: +73.82%
Mar 28, 2025
Initiates: Overweight
Price Target: $120
Current: $91.65
Upside: +30.93%
Feb 21, 2025
Maintains: Neutral
Price Target: $38 → $36
Current: $24.45
Upside: +47.24%
Jan 29, 2025
Maintains: Overweight
Price Target: $420 → $445
Current: $392.76
Upside: +13.30%
Jan 24, 2025
Maintains: Overweight
Price Target: $575 → $675
Current: $467.54
Upside: +44.37%
Dec 17, 2024
Upgrades: Neutral
Price Target: $12 → $13
Current: $7.27
Upside: +78.82%
Dec 16, 2024
Maintains: Overweight
Price Target: $100 → $110
Current: $108.09
Upside: +1.77%
Dec 12, 2024
Maintains: Overweight
Price Target: $280 → $330
Current: $352.82
Upside: -6.47%
Nov 5, 2024
Initiates: Overweight
Price Target: $32
Current: $11.86
Upside: +169.81%
Oct 30, 2024
Maintains: Overweight
Price Target: $30 → $40
Current: $36.04
Upside: +10.99%
Oct 25, 2024
Maintains: Neutral
Price Target: $75 → $85
Current: $78.40
Upside: +8.42%
Sep 9, 2024
Initiates: Neutral
Price Target: $90
Current: $78.71
Upside: +14.34%
Aug 8, 2024
Maintains: Neutral
Price Target: $53 → $50
Current: $31.19
Upside: +60.31%
May 8, 2024
Downgrades: Neutral
Price Target: $15 → $8
Current: $7.37
Upside: +8.62%
Feb 23, 2024
Downgrades: Neutral
Price Target: $284 → $250
Current: $287.09
Upside: -12.92%
Dec 20, 2023
Maintains: Neutral
Price Target: $10 → $16
Current: $18.86
Upside: -15.16%
Nov 8, 2023
Maintains: Underweight
Price Target: $8 → $7
Current: $8.53
Upside: -17.94%
Feb 23, 2023
Maintains: Neutral
Price Target: $15 → $17
Current: $15.30
Upside: +11.11%
Oct 20, 2022
Maintains: Overweight
Price Target: $125 → $118
Current: $131.95
Upside: -10.57%
Jan 27, 2022
Maintains: Overweight
Price Target: $116 → $156
Current: $186.39
Upside: -16.30%
Dec 17, 2021
Downgrades: Neutral
Price Target: $130 → $105
Current: $94.07
Upside: +11.62%
May 5, 2020
Maintains: Neutral
Price Target: $55 → $40
Current: $90.91
Upside: -56.00%